03/06/20 -"FY19/20 reported EPS was impacted by higher than expected financial expenses (due to increased interest expenses from new funding and interest on lease liabilities under IFRS 16) and tax charges ..."
Pages
66
Language
English
Published on
03/06/20
You may also be interested by these reports :
18/03/24
DiaSorin’s 2023 results were in line with street expectations, however the profitability guidance miss disappointed investors. Healthy performance by ...
14/03/24
Q4 sales met the street’s expectations. Industrial Applications reported strong growth and Clinical Applications ended on a decent note, despite ...
12/03/24
First take: Growing profitability with 3-18% beat on expectations
08/03/24
When we last teased on Elekta’s (BUY; Sweden) investment case in October 2022, Elekta grabbed the investors’ much-needed attention (up >35% since ...